Alces Bioworks, Inc.
@alcesbioworks.bsky.social
Alces Bioworks uses revolutionary protein design technologies to create superior affinity reagents for its customers. Affinity reagents made better and faster. https://www.alcesbioworks.com
Reposted by Alces Bioworks, Inc.
AlphaFold DB v6 (synced with UniProt 2025_03) is live! Here are the details:
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
October 21, 2025 at 1:00 PM
AlphaFold DB v6 (synced with UniProt 2025_03) is live! Here are the details:
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
Totals v4 → v6: 241,070,489 entries.
Since v4: +65,711,653 added, 39,324,993 removed, 276,539 changed (in sequence), 175,082,297 unchanged (metadata refresh, relabelled v6). Details 👇
Reposted by Alces Bioworks, Inc.
Scientists have designed an interleukin-21 mimic with increased stability and capacity to induce more potent antitumor activity than the native protein, which could inform improved #immunotherapies.
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Design of a potent interleukin-21 mimic for cancer immunotherapy
A de novo IL-21 mimic, 21h10, exhibits improved stability and potent antitumor activity in vivo compared with native IL-21.
scim.ag
October 21, 2025 at 3:08 PM
Scientists have designed an interleukin-21 mimic with increased stability and capacity to induce more potent antitumor activity than the native protein, which could inform improved #immunotherapies.
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Learn more in #ScienceImmunology: https://scim.ag/47jQLSW
Reposted by Alces Bioworks, Inc.
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
schedule
introduction and membership
Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...
bpdmc.org
October 17, 2025 at 8:27 PM
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
Reposted by Alces Bioworks, Inc.
Success rates for Europe’s leading research grants are declining as a surge in applications far outweighs the funds available
go.nature.com/479Sni6
go.nature.com/479Sni6
Is academic research becoming too competitive? Nature examines the data
Applications for European research grants increased in 2025. Scientists say they’re feeling the competition.
go.nature.com
October 17, 2025 at 10:12 AM
Success rates for Europe’s leading research grants are declining as a surge in applications far outweighs the funds available
go.nature.com/479Sni6
go.nature.com/479Sni6
Nabla expects first-in-human data from its AI-designed molecules within one to two years, according to Reuters.
Takeda Pharmaceuticals and Nabla Bio, a start-up focused on designing de novo proteins with artificial intelligence, have signed a second round of collaboration.
cen.acs.org/pharmaceutic... #chemsky 🧪
cen.acs.org/pharmaceutic... #chemsky 🧪
AI-based protein discovery start-up strikes a second deal with Takeda
Nabla Bio's platform is becoming popular with big pharma companies
cen.acs.org
October 17, 2025 at 2:28 PM
Nabla expects first-in-human data from its AI-designed molecules within one to two years, according to Reuters.
Reposted by Alces Bioworks, Inc.
On course to end new HIV cases in the UK by 2030.
First injection to stop HIV approved
The shot, given six times a year or every other month, is an alternative to taking daily pills to protect against ever catching the virus.
www.bbc.com
October 17, 2025 at 6:10 AM
On course to end new HIV cases in the UK by 2030.
Reposted by Alces Bioworks, Inc.
🚨Our paper is out! 🥳
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
Hijacking a bacterial ABC transporter for genetic code expansion - Nature
Bacterial ATP-binding cassette (ABC) transporters can be utilized and engineered to transport non-canonical amino acids into Escherichia coli for highly efficient synthesis of proteins with novel func...
www.nature.com
October 16, 2025 at 2:06 PM
🚨Our paper is out! 🥳
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
Hijacking a bacterial ABC transporter for efficient genetic code expansion.
Many congrats to everyone involved - a multi-year effort led by @taruniype.bsky.social @maxfottner.bsky.social
www.nature.com/articles/s41...
it all started years ago with a failed experiment
🧵👇 1/9
A new blog post on our website: how to measure binding affinity of an Alcein!
alcesbioworks.com/how-we-measu...
alcesbioworks.com/how-we-measu...
September 26, 2025 at 6:17 PM
A new blog post on our website: how to measure binding affinity of an Alcein!
alcesbioworks.com/how-we-measu...
alcesbioworks.com/how-we-measu...
Reposted by Alces Bioworks, Inc.
At the Berlin node of a global hackathon, teams raced to develop artificial intelligence tools to accelerate the design of drugs and materials. https://scim.ag/3VuZyvR
Researchers customize AI tools at global ‘hackathon’
More than 1200 scientists and developers explore how large language models can be applied to materials science and chemistry
www.science.org
September 22, 2025 at 11:12 PM
At the Berlin node of a global hackathon, teams raced to develop artificial intelligence tools to accelerate the design of drugs and materials. https://scim.ag/3VuZyvR
Reposted by Alces Bioworks, Inc.
Nvidia to invest up to $100bn in OpenAI on.ft.com/4mxtu5N
Nvidia to invest up to $100bn in OpenAI
Partnership will support massive build-out of data centres for artificial intelligence
on.ft.com
September 22, 2025 at 4:43 PM
Nvidia to invest up to $100bn in OpenAI on.ft.com/4mxtu5N
Reposted by Alces Bioworks, Inc.
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design
In this review, Fox et al. discuss how artificial intelligence has transformed our
ability to design new-to-nature proteins that bind target proteins with high affinity
and specificity. The authors de...
www.cell.com
September 5, 2025 at 1:30 PM
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design
In this review, Fox et al. discuss how artificial intelligence has transformed our
ability to design new-to-nature proteins that bind target proteins with high affinity
and specificity. The authors de...
www.cell.com
September 5, 2025 at 1:30 PM
New review on AI and protein design...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Code to complex: AI-driven de novo binder design: Structure www.cell.com/structure/fu...
Reposted by Alces Bioworks, Inc.
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
August 20, 2025 at 1:29 PM
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
August 20, 2025 at 1:29 PM
We’re thrilled to announce that Alces Bioworks has joined the NVIDIA Inception program!
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
This supports our mission to create for our customers superior affinity reagents we call Alceins™.
#NVIDIAInception #AI #BiotechInnovation
Alces Bioworks is happy to announce its new website! 🎉
www.alcesbioworks.com 🫎
Check it out and let us know what you think. 🧑🔬
If you need a new affinity reagent🧪, we are more than happy to take your order.
www.alcesbioworks.com 🫎
Check it out and let us know what you think. 🧑🔬
If you need a new affinity reagent🧪, we are more than happy to take your order.
June 27, 2025 at 8:51 PM
Alces Bioworks is happy to announce its new website! 🎉
www.alcesbioworks.com 🫎
Check it out and let us know what you think. 🧑🔬
If you need a new affinity reagent🧪, we are more than happy to take your order.
www.alcesbioworks.com 🫎
Check it out and let us know what you think. 🧑🔬
If you need a new affinity reagent🧪, we are more than happy to take your order.
Poorly performing antibodies have plagued biomedical sciences for decades...
www.nature.com/articles/d41...
www.nature.com/articles/d41...
The antibodies don’t work! The race to rid labs of molecules that ruin experiments
Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.
www.nature.com
June 17, 2025 at 6:59 PM
Poorly performing antibodies have plagued biomedical sciences for decades...
www.nature.com/articles/d41...
www.nature.com/articles/d41...
